PRAKASH MASAND to Antipsychotic Agents
This is a "connection" page, showing publications PRAKASH MASAND has written about Antipsychotic Agents.
Connection Strength
3.643
-
The real-world impact of cariprazine on short- and long-term disability outcomes among commercially insured patients in the United States. J Med Econ. 2025 Dec; 28(1):335-345.
Score: 0.712
-
Aripiprazole augmentation for major depressive disorder: dosing patterns in a naturalistic treatment setting. Int Clin Psychopharmacol. 2014 Mar; 29(2):116-9.
Score: 0.332
-
Clinical Global Impression of Improvement (CGI-I) as a valid proxy measure for remission in schizophrenia: analyses of ziprasidone clinical study data. Schizophr Res. 2011 Mar; 126(1-3):174-83.
Score: 0.266
-
Criteria for defining symptomatic and sustained remission in bipolar I disorder: a post-hoc analysis of a 26-week aripiprazole study (study CN138-010). Psychopharmacol Bull. 2008; 41(2):12-23.
Score: 0.216
-
Differential pharmacology of atypical antipsychotics: clinical implications. Am J Health Syst Pharm. 2007 Jan 15; 64(2 Suppl 1):S3-8; quiz S24-5.
Score: 0.202
-
Improving adherence to antipsychotic pharmacotherapy. Curr Clin Pharmacol. 2006 Jan; 1(1):47-56.
Score: 0.188
-
Metabolic and endocrine disturbances in psychiatric disorders: a multidisciplinary approach to appropriate atypical antipsychotic utilization. CNS Spectr. 2005 Oct; 10(10):suppl14 1-15.
Score: 0.185
-
Second-generation antipsychotics and the metabolic syndrome. Curr Psychiatry Rep. 2005 Jun; 7(3):153-4.
Score: 0.181
-
Clinical effectiveness of atypical antipsychotics in elderly patients with psychosis. Eur Neuropsychopharmacol. 2004 Nov; 14 Suppl 4:S461-9.
Score: 0.174
-
Psychotic symptoms in patients with medical disorders. Curr Psychiatry Rep. 2004 Jun; 6(3):216-24.
Score: 0.169
-
Long-acting injectable antipsychotics in the elderly: guidelines for effective use. Drugs Aging. 2003; 20(15):1099-110.
Score: 0.153
-
Prescribing conventional antipsychotics in the era of novel antipsychotics: informed consent issues. Am J Ther. 2002 Nov-Dec; 9(6):484-7.
Score: 0.151
-
Cariprazine for the treatment of bipolar mania with mixed features: A post hoc pooled analysis of 3 trials. J Affect Disord. 2019 10 01; 257:600-606.
Score: 0.120
-
Genetic Variants Within Molecular Targets of Antipsychotic Treatment: Effects on Treatment Response, Schizophrenia Risk, and Psychopathological Features. J Mol Neurosci. 2018 Jan; 64(1):62-74.
Score: 0.107
-
Genetic Variants Within Key Nodes of the Cascade of Antipsychotic Mechanisms: Effects on Antipsychotic Response and Schizophrenia Psychopathology in a Naturalistic Treatment Setting in Two Independent Korean and Italian Samples. Adv Ther. 2017 06; 34(6):1482-1497.
Score: 0.104
-
Investigational dopamine antagonists for the treatment of schizophrenia. Expert Opin Investig Drugs. 2017 Jun; 26(6):687-698.
Score: 0.104
-
A 13-week, randomized double-blind, placebo-controlled, cross-over trial of ziprasidone in bipolar spectrum disorder. J Clin Psychopharmacol. 2015 Jun; 35(3):319-23.
Score: 0.090
-
A 6 week randomized double-blind placebo-controlled trial of ziprasidone for the acute depressive mixed state. PLoS One. 2012; 7(4):e34757.
Score: 0.073
-
Clinical variables associated with early administration of antipsychotics in bipolar mania. Prog Neuropsychopharmacol Biol Psychiatry. 2006 Jan; 30(1):151-4.
Score: 0.047
-
Comparison between long-acting injectable aripiprazole versus paliperidone palmitate in the treatment of schizophrenia: systematic review and indirect treatment comparison. Int Clin Psychopharmacol. 2017 09; 32(5):235-248.
Score: 0.026
-
The influence of AHI1 variants on the diagnosis and treatment outcome in schizophrenia. Int J Mol Sci. 2015 Jan 22; 16(2):2517-29.
Score: 0.022
-
Asenapine, blonanserin, iloperidone, lurasidone, and sertindole: distinctive clinical characteristics of 5 novel atypical antipsychotics. Clin Neuropharmacol. 2013 Nov-Dec; 36(6):223-38.
Score: 0.020